Histologic transformation from NSCLC to small cell lung cancer (SCLC) is a known mechanism of resistance to third-generation EGFR-TKIs in second-line osimertinib treatment [70,97,134]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.